2003. Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin Prostate Cancer 2:24–31. :Steiner MS & Pound CR 2003 Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade ...
The first-in-human Phase I/IIa clinical trial will be conducted in the United States and consist of two parts. The first part is a multicenter, open-label trial with two dosing cohorts of six patients each to assess safety, tolerability, and first signs for efficacy of AMT-260 in patients...
Phase IIa/IIb clinical trial of NC-6004 (Nanoparticle Cisplatin) plus Pembrolizumab in patients with head and neck cancer (HNSCC) who have failed platinum or a platinum-containing regimendoi:10.1016/s0959-8049(20)31164-3A. OsadaL. Mangel...
(phase IV) ●新藥經過核准上市後 ,所進行的研究 ,又稱為銷售後試驗(post-marketing trial) ,或是註冊後試驗 (post-registration trial) ●目標為持續評估新藥上市後的藥效和安全評估 ●另一目標為評估新藥對健康經濟學(health economics) 的影響 體外測試(in vitro testing) 第0期人體試驗 臨床前期發展 活體...
Tailored solutions at every phase Through each phase of development, Quest can support your pursuit of getting the right therapy to the people who need it. Early clinical (Phase I-IIa) Late clinical (Phase IIb-III) Phase IV studies
Phase I/IIa clinical trial utilizing autologous MSCs for Rheumatoid arthritis. Learn More Osteoarthritis Phase II Phase II clinical trial utilizing autologous MSCs for osteoarthritis. Learn More Alzheimer’s Disease Texas A&M University Partnership Major partnership study with Texas A&M University IRM us...
Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents Expansion of ongoing trial to include adolescents 12-17 years of age reflects commitment to people of all ages affected by pandemic April 2, 2021 Share New...
Spago Nanomedical AB announced that the final step in the preparations for the clinical phase I/IIa trial in cancer patients, Tumorad-01, with its leading candidate drug 177Lu-SN201 has begun in Australia. LUND, SWEDEN /ACCESSWIRE/ May 23, 2023 / Spago Nanom...
This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib (VS-6063), and the dual RAF/MEK inhibitor, avutometinib (VS-6766) in patients with advanced solid tumours. VS-6766 (RO5126766) is the same compound as CH512...
Data of Phase IIa clinical trial (166 patients) showed that after 12 weeks treatment, the non-progression rate (PFR) is 68.42%, progression-free survival (PFS) is 5.63 months, overall survival (OS) is 12.33 months, and objective remission rate (ORR) is 12.65%, of which the ORR of Alveo...